AR035750A1 - Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes - Google Patents
Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantesInfo
- Publication number
- AR035750A1 AR035750A1 ARP020100540A ARP020100540A AR035750A1 AR 035750 A1 AR035750 A1 AR 035750A1 AR P020100540 A ARP020100540 A AR P020100540A AR P020100540 A ARP020100540 A AR P020100540A AR 035750 A1 AR035750 A1 AR 035750A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- hydrogen
- preparation
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Uso de un compuesto N-(piridinilamino) indoles de la fórmula (1) en la cual: m es 0, 1 o 2; n es 0, 1 o 2; p es 0 o 1; cada R es independientemente hidrógeno, halógeno, trifluorometilo, alquilo C1-6, alcoxi C1-6, benciloxi, hidroxi, nitro o amino; cada R1 es independientemente hidrógeno, alquilo C1-6, alquenilo C1-6, alcanoílo C1-6, halógeno, ciano -C(O)C-alquilo C1-6, alquilen C1-6-CN, alquilen C1-6-NR'R'', donde cada uno de R' y R'' es independientemente hidrógeno o alquilo C1-6; alquilen C1-6-OC(O)alquilo C1-6 o -CH(OH)R4, donde R4 es hidrógeno o alquilo C1-6; R2 es hidrógeno, alquilo C1-6, optativamente sustituido con halógeno, hidroxi o benciloxi, alquenilo C1-6, alquinilo C1-6, -CO2-alquilo C1-6, o -R5-NR'R'', donde R5 es alquileno C1-6, alquenileno C1-6, o alquinileno C1-6 y cada uno de R' y R'' es independientemente hidrógeno, alquilo C1-6 o, de lo contrario, el grupo -NR'R'' en su totalidad es 1-pirrolidinilo y R3 es hidrógeno, nitro, amino, halógeno, alcoxi C1-6, hidroxi o alquilo C1-6, o una sal farmacéuticamente aceptable del mismo para la preparación de un medicamento para el tratamiento de las Enfermedades Desmielinizantes a un paciente que lo necesita.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26884601P | 2001-02-15 | 2001-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035750A1 true AR035750A1 (es) | 2004-07-07 |
Family
ID=23024747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100540A AR035750A1 (es) | 2001-02-15 | 2002-02-15 | Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes |
Country Status (39)
| Country | Link |
|---|---|
| US (10) | US6967210B2 (es) |
| EP (1) | EP1368031A2 (es) |
| JP (3) | JP2004518711A (es) |
| KR (3) | KR100951540B1 (es) |
| CN (2) | CN100522164C (es) |
| AP (1) | AP1749A (es) |
| AR (1) | AR035750A1 (es) |
| AU (3) | AU2002247200B9 (es) |
| BR (1) | BR0207272A (es) |
| CA (1) | CA2438712A1 (es) |
| CO (1) | CO5390085A1 (es) |
| CR (1) | CR7023A (es) |
| CZ (1) | CZ20032172A3 (es) |
| EA (2) | EA012409B1 (es) |
| EC (1) | ECSP024218A (es) |
| EE (1) | EE200300363A (es) |
| GB (1) | GB0119435D0 (es) |
| HK (1) | HK1080361B (es) |
| HR (1) | HRP20030652A2 (es) |
| HU (1) | HUP0303203A3 (es) |
| IL (2) | IL157341A0 (es) |
| MA (1) | MA26152A1 (es) |
| ME (1) | MEP21208A (es) |
| MX (1) | MXPA03006110A (es) |
| MY (1) | MY157745A (es) |
| NO (1) | NO20033622L (es) |
| NZ (4) | NZ544720A (es) |
| OA (1) | OA12549A (es) |
| PA (1) | PA8540101A1 (es) |
| PE (1) | PE20040175A1 (es) |
| PL (1) | PL363638A1 (es) |
| SG (1) | SG134170A1 (es) |
| SK (1) | SK10392003A3 (es) |
| TR (4) | TR200301330T2 (es) |
| TW (1) | TWI325319B (es) |
| UA (2) | UA80394C2 (es) |
| WO (1) | WO2002064126A2 (es) |
| YU (1) | YU62903A (es) |
| ZA (1) | ZA200306124B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
| BR0317606A (pt) * | 2002-12-20 | 2005-11-29 | Dynogen Pharmaceuticals Inc | Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta) |
| AU2004207010A1 (en) * | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channel modulators |
| US20040198822A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmacueticals, Inc. | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators |
| GT200500063A (es) * | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| GB0510164D0 (en) * | 2005-04-28 | 2005-06-22 | Paradigm Therapeutics Ltd | Ion channel |
| FR2892022B1 (fr) * | 2005-10-19 | 2008-01-04 | Urogene Sa | Traitement des symptomes de l'irritation de la vessie |
| FR2892021B1 (fr) * | 2005-10-19 | 2008-01-04 | Urogene | Traitement de l'incontinence urinaire d'effort et mixte |
| US8420593B1 (en) * | 2006-06-16 | 2013-04-16 | Landon C. G. Miller | Compositions and methods for regulating membrane potential |
| DE102008044844B4 (de) * | 2008-08-28 | 2018-08-30 | Siemens Healthcare Gmbh | Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes |
| KR101862539B1 (ko) * | 2010-03-26 | 2018-05-31 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 반도체 장치 |
| US20130184316A1 (en) * | 2010-07-15 | 2013-07-18 | Andrew Hornstein | Methods for diagnosing and treating concussive disorders |
| EP2995305B1 (en) * | 2011-01-28 | 2020-03-04 | Acorda Therapeutics, Inc. | Use of potassium channel blockers to treat cerebral palsy |
| TWI592156B (zh) * | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| EP3727587A4 (en) | 2017-12-22 | 2022-02-23 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS) |
| CN116723870A (zh) * | 2021-01-20 | 2023-09-08 | 拉什大学医学中心 | 球形细胞脑白质营养不良症或克拉伯病的改良治疗 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US4970218A (en) * | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| ATE115143T1 (de) * | 1987-04-24 | 1994-12-15 | Hoechst Roussel Pharma | N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel. |
| IL95251A (en) * | 1989-08-02 | 1996-08-04 | Hoechst Roussel Pharma | 2,3-Dihydro-1- (pyridinylamino) - indoles, a method for their preparation and use as drugs |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| DE4325491A1 (de) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels |
| US5459274A (en) * | 1994-05-13 | 1995-10-17 | Hoechst-Roussel Pharmaceuticals Inc. | Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines |
| US5565475A (en) * | 1994-11-08 | 1996-10-15 | Muhlhauser; Mark A. | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives |
| EP0731108A1 (en) * | 1995-03-10 | 1996-09-11 | Boehringer Mannheim Gmbh | Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes |
| FR2754147B1 (fr) | 1996-10-03 | 2000-02-04 | Mbh Technologies Sa | Installation et procede pour le traitement de carcasses |
| DK1056754T3 (da) * | 1998-01-29 | 2004-02-16 | Bristol Myers Squibb Co | Phosphatderivater af diaryl-1,3,4-oxadiazolon |
| WO2001004091A1 (en) * | 1999-07-09 | 2001-01-18 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2001
- 2001-08-09 GB GBGB0119435.6A patent/GB0119435D0/en not_active Ceased
-
2002
- 2002-02-14 BR BR0207272-6A patent/BR0207272A/pt not_active IP Right Cessation
- 2002-02-14 JP JP2002563920A patent/JP2004518711A/ja not_active Ceased
- 2002-02-14 IL IL15734102A patent/IL157341A0/xx unknown
- 2002-02-14 EE EEP200300363A patent/EE200300363A/xx unknown
- 2002-02-14 AU AU2002247200A patent/AU2002247200B9/en not_active Ceased
- 2002-02-14 KR KR1020037010691A patent/KR100951540B1/ko not_active IP Right Cessation
- 2002-02-14 KR KR1020087031854A patent/KR20090005254A/ko not_active Application Discontinuation
- 2002-02-14 NZ NZ544720A patent/NZ544720A/en unknown
- 2002-02-14 UA UA2003098376A patent/UA80394C2/uk unknown
- 2002-02-14 ME MEP-212/08A patent/MEP21208A/xx unknown
- 2002-02-14 EA EA200600896A patent/EA012409B1/ru not_active IP Right Cessation
- 2002-02-14 TR TR2003/01330T patent/TR200301330T2/xx unknown
- 2002-02-14 EA EA200300882A patent/EA011319B1/ru not_active IP Right Cessation
- 2002-02-14 SG SG200505802-9A patent/SG134170A1/en unknown
- 2002-02-14 US US10/076,191 patent/US6967210B2/en not_active Expired - Lifetime
- 2002-02-14 AP APAP/P/2003/002834A patent/AP1749A/en active
- 2002-02-14 CA CA002438712A patent/CA2438712A1/en not_active Abandoned
- 2002-02-14 WO PCT/US2002/005501 patent/WO2002064126A2/en active Application Filing
- 2002-02-14 NZ NZ527011A patent/NZ527011A/en unknown
- 2002-02-14 HU HU0303203A patent/HUP0303203A3/hu unknown
- 2002-02-14 CZ CZ20032172A patent/CZ20032172A3/cs unknown
- 2002-02-14 SK SK1039-2003A patent/SK10392003A3/sk unknown
- 2002-02-14 OA OA1200300199A patent/OA12549A/en unknown
- 2002-02-14 EP EP02714974A patent/EP1368031A2/en not_active Withdrawn
- 2002-02-14 TR TR2008/00692T patent/TR200800692T2/xx unknown
- 2002-02-14 CN CNB2005100597348A patent/CN100522164C/zh not_active Expired - Fee Related
- 2002-02-14 MX MXPA03006110A patent/MXPA03006110A/es active IP Right Grant
- 2002-02-14 NZ NZ556697A patent/NZ556697A/en unknown
- 2002-02-14 CN CNA028048644A patent/CN1529598A/zh active Pending
- 2002-02-14 KR KR1020087031855A patent/KR100951542B1/ko not_active IP Right Cessation
- 2002-02-14 NZ NZ539159A patent/NZ539159A/en unknown
- 2002-02-14 YU YU62903A patent/YU62903A/sh unknown
- 2002-02-14 TR TR2008/00691T patent/TR200800691T2/xx unknown
- 2002-02-14 TR TR2008/00693T patent/TR200800693T2/xx unknown
- 2002-02-14 PL PL02363638A patent/PL363638A1/xx not_active Application Discontinuation
- 2002-02-15 EC EC2002004218A patent/ECSP024218A/es unknown
- 2002-02-15 AR ARP020100540A patent/AR035750A1/es unknown
- 2002-02-15 TW TW091102861A patent/TWI325319B/zh not_active IP Right Cessation
- 2002-02-15 CO CO02013025A patent/CO5390085A1/es not_active Application Discontinuation
- 2002-02-15 MY MYPI20020518A patent/MY157745A/en unknown
- 2002-02-18 PA PA20028540101A patent/PA8540101A1/es unknown
- 2002-02-26 PE PE2002000159A patent/PE20040175A1/es not_active Application Discontinuation
-
2003
- 2003-07-11 MA MA27235A patent/MA26152A1/fr unknown
- 2003-07-16 CR CR7023A patent/CR7023A/es unknown
- 2003-08-07 ZA ZA200306124A patent/ZA200306124B/xx unknown
- 2003-08-11 IL IL157341A patent/IL157341A/en not_active IP Right Cessation
- 2003-08-13 HR HR20030652A patent/HRP20030652A2/hr not_active Application Discontinuation
- 2003-08-14 NO NO20033622A patent/NO20033622L/no not_active Application Discontinuation
-
2004
- 2004-02-03 US US10/770,655 patent/US20040157888A1/en not_active Abandoned
- 2004-02-03 US US10/770,656 patent/US20040157889A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/079,366 patent/US7179821B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/079,327 patent/US7230015B2/en not_active Expired - Lifetime
- 2005-09-27 US US11/236,145 patent/US7534803B2/en not_active Expired - Fee Related
-
2006
- 2006-01-05 HK HK06100186.8A patent/HK1080361B/zh not_active IP Right Cessation
- 2006-04-04 UA UAA200603708A patent/UA88773C2/ru unknown
-
2008
- 2008-03-13 AU AU2008201179A patent/AU2008201179B2/en not_active Ceased
-
2009
- 2009-04-06 JP JP2009091807A patent/JP2009185045A/ja not_active Abandoned
- 2009-04-29 US US12/420,407 patent/US20090209594A1/en not_active Abandoned
- 2009-04-29 US US12/420,390 patent/US20090281147A1/en not_active Abandoned
- 2009-04-29 US US12/420,416 patent/US20090209595A1/en not_active Abandoned
- 2009-04-29 US US12/420,381 patent/US20090270458A1/en not_active Abandoned
- 2009-11-19 AU AU2009238332A patent/AU2009238332A1/en not_active Abandoned
-
2010
- 2010-02-16 JP JP2010030929A patent/JP2010120958A/ja not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035750A1 (es) | Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes | |
| BR0213358A (pt) | Uso de flibanserina | |
| UY27740A1 (es) | Nuevos compuestos | |
| AR048197A1 (es) | Metodos para tratar la esquizofrenia y/o anomalias de glucorregulacion | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| AR058163A1 (es) | Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona | |
| EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| BR0311337A (pt) | Uso oftalmológico de roflumilast para o tratamento de doenças do olho | |
| UY28369A1 (es) | Agentes terapéuticos | |
| NO20065878L (no) | Terapeutiske forbindelser | |
| HUP0203325A2 (hu) | Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| BR0012082A (pt) | Formulação farmacêutica para administração compreendendo morfina e seu uso | |
| UY28896A1 (es) | Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros | |
| BRPI0408295A (pt) | uso de um composto | |
| AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
| AR035889A1 (es) | Citrato de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]hexadeca-2(11),3,5,7,9- pentaeno y composiciones farmaceuticas que la contienen y su uso para la elaboracion de medicamentos | |
| BRPI0513943A (pt) | uso de um composto ou de um sal farmaceuticamente aceitável | |
| PL360492A1 (en) | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| HUP0300863A2 (hu) | N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény | |
| CR8584A (es) | Piperazinas derivadas de urea para el tratamiento de la endometrosis | |
| BRPI0508848A (pt) | uso de pelo menos um composto, sistema iontoforético para a administração de um composto através da pele, cartucho, e, kit | |
| BR9708171A (pt) | Uso de derivados de 4-fenil-3,6-di-hidro-2h-piridila como bloqueadores de subtipo de receptor nmda | |
| BR0316751A (pt) | Análogos de gabapentina para fibromialgia e outros distúrbios relacionados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |